In a deal that ends a three-year U.S. court battle over patent infringement claims for Lambert-Eaton myasthenic syndrome (LEMS)…
Articles by Marisa Wexler, MS
A company called Vibe Biotechnology has launched to build a community of patients, scientists, and other partners to find…
Long-term treatment with Firdapse is generally well-tolerated by people with Lambert-Eaton myasthenic syndrome (LEMS), according to a study…
The potential risks and benefits of several policy changes that could affect the landscape of developing treatments for rare diseases…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
A branch of the European Medicines Agency (EMA) has recommended that Amifampridine SERB, a generic version of Firdapse,…
The Federal Court of Canada has issued a decision that, for the second time, sets aside Health Canada’s approval of…
Catalyst Pharmaceuticals has secured three new U.S. patents covering the use of Firdapse (amifampridine) for treating Lambert-Eaton…
A new podcast, called LEMS Aware, is launching this month on international Rare Disease Day with the goal of connecting…
People affected by Lambert-Eaton myasthenic syndrome (LEMS) and other rare diseases in the U.S. are encouraged to share…